JP2014523408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523408A5 JP2014523408A5 JP2014514023A JP2014514023A JP2014523408A5 JP 2014523408 A5 JP2014523408 A5 JP 2014523408A5 JP 2014514023 A JP2014514023 A JP 2014514023A JP 2014514023 A JP2014514023 A JP 2014514023A JP 2014523408 A5 JP2014523408 A5 JP 2014523408A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- variable region
- sequence
- chain comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 238000006467 substitution reaction Methods 0.000 claims 9
- 230000037430 deletion Effects 0.000 claims 8
- 238000012217 deletion Methods 0.000 claims 8
- 230000037431 insertion Effects 0.000 claims 8
- 238000003780 insertion Methods 0.000 claims 8
- 208000026278 immune system disease Diseases 0.000 claims 4
- 238000013508 migration Methods 0.000 claims 3
- 230000005012 migration Effects 0.000 claims 3
- 210000000440 neutrophil Anatomy 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 claims 1
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 claims 1
- 101000867983 Homo sapiens C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 206010057249 Phagocytosis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000000670 ligand binding assay Methods 0.000 claims 1
- 230000008782 phagocytosis Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11168787 | 2011-06-06 | ||
| EP11168787.7 | 2011-06-06 | ||
| US201161505137P | 2011-07-07 | 2011-07-07 | |
| US61/505,137 | 2011-07-07 | ||
| EP12159172.1 | 2012-03-13 | ||
| EP12159172 | 2012-03-13 | ||
| PCT/EP2012/060524 WO2012168199A1 (en) | 2011-06-06 | 2012-06-04 | Therapeutic antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016237458A Division JP6416177B2 (ja) | 2011-06-06 | 2016-12-07 | 治療抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523408A JP2014523408A (ja) | 2014-09-11 |
| JP2014523408A5 true JP2014523408A5 (OSRAM) | 2015-07-23 |
| JP6141834B2 JP6141834B2 (ja) | 2017-06-07 |
Family
ID=47295509
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514023A Active JP6141834B2 (ja) | 2011-06-06 | 2012-06-04 | 治療抗体 |
| JP2016237458A Active JP6416177B2 (ja) | 2011-06-06 | 2016-12-07 | 治療抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016237458A Active JP6416177B2 (ja) | 2011-06-06 | 2016-12-07 | 治療抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US8613926B2 (OSRAM) |
| EP (3) | EP3798230B1 (OSRAM) |
| JP (2) | JP6141834B2 (OSRAM) |
| KR (1) | KR101978757B1 (OSRAM) |
| CN (1) | CN103596982B (OSRAM) |
| AU (1) | AU2012266487B2 (OSRAM) |
| BR (1) | BR112013031198B1 (OSRAM) |
| CA (1) | CA2838497C (OSRAM) |
| DK (3) | DK2718322T3 (OSRAM) |
| ES (2) | ES2929575T3 (OSRAM) |
| IL (1) | IL229254A (OSRAM) |
| PL (2) | PL3424953T3 (OSRAM) |
| PT (1) | PT3424953T (OSRAM) |
| RU (1) | RU2616881C2 (OSRAM) |
| TW (1) | TWI564305B (OSRAM) |
| WO (1) | WO2012168199A1 (OSRAM) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2616881C2 (ru) * | 2011-06-06 | 2017-04-18 | Ново Нордиск А/С | Терапевтические антитела |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| SG11201601844TA (en) * | 2013-09-13 | 2016-04-28 | Beigene Ltd | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| CN107074957B (zh) * | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| WO2015140591A1 (en) * | 2014-03-21 | 2015-09-24 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
| CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| CA2955788C (en) | 2014-07-22 | 2024-01-16 | Ziyong Sun | Anti-pd-1 antibodies |
| US10435470B2 (en) | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| US20170328898A1 (en) * | 2014-10-31 | 2017-11-16 | Cell Trend GmbH | Diagnosis of an autoimmune disease using detection of antibodies directed against c5a-receptor |
| BR112018009129A2 (pt) * | 2015-11-04 | 2019-02-26 | J. PRICEMAN Saul | receptores de antígeno quimérico que visam her2 |
| CA3005986A1 (en) * | 2015-11-23 | 2017-06-01 | Innate Pharma | Cd39 vascular isoform targeting agents |
| HUE064791T2 (hu) | 2015-11-25 | 2024-04-28 | Visterra Inc | APRIL ellenes antitest molekulák és alkalmazásaik |
| CN106957366B (zh) * | 2016-01-12 | 2022-02-01 | 上海昀怡健康科技发展有限公司 | 一种C5aR抗体及其制备方法和应用 |
| AR107505A1 (es) | 2016-01-22 | 2018-05-09 | Merck Sharp & Dohme | Anticuerpos anti-factor de la coagulación xi |
| WO2017218371A1 (en) | 2016-06-14 | 2017-12-21 | Merck Sharp & Dohme Corp. | Anti-coagulation factor xi antibodies |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| AU2017313085B2 (en) | 2016-08-19 | 2024-06-20 | Beone Medicines I Gmbh | Use of a combination comprising a Btk inhibitor for treating cancers |
| TWI774726B (zh) | 2017-01-25 | 2022-08-21 | 英屬開曼群島商百濟神州有限公司 | (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途 |
| MX2019010848A (es) | 2017-03-16 | 2019-10-30 | Innate Pharma | Composiciones y procedimientos para el tratamiento del cancer. |
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| KR20240149979A (ko) * | 2017-05-25 | 2024-10-15 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 중쇄 불변 영역을 포함하는 항체 |
| TWI877099B (zh) | 2017-06-26 | 2025-03-21 | 英屬開曼群島商百濟神州有限公司 | 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途 |
| WO2019034580A1 (en) * | 2017-08-14 | 2019-02-21 | Morphosys Ag | HUMANIZED ANTIBODIES FOR CD3 |
| WO2019092148A1 (en) * | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| JP7500442B2 (ja) | 2018-06-18 | 2024-06-17 | イナート・ファルマ・ソシエテ・アノニム | 癌を処置するための組成物及び方法 |
| JP7654548B2 (ja) | 2018-09-17 | 2025-04-01 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 抗ｋｌｒｇ１抗体 |
| US20220041719A1 (en) * | 2018-12-05 | 2022-02-10 | Morphosys Ag | Multispecific antigen-binding molecules |
| BR112021017860A2 (pt) * | 2019-03-14 | 2021-12-07 | Morphosys Ag | Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica |
| US20230220042A1 (en) * | 2019-12-03 | 2023-07-13 | Shanghai Jiao Tong University School Of Medicine | Antibody fc region having enhanced binding affinity to fcyriib |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| GB2595299B (en) * | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| JP2023537417A (ja) | 2020-08-12 | 2023-08-31 | イナート・ファルマ・ソシエテ・アノニム | アブドラリマブによる皮下抗Ｃ５ａＲアンタゴニスト治療レジメン |
| US20230374147A1 (en) | 2020-11-02 | 2023-11-23 | Hummingbird Bioscience Pte. Ltd. | Bcma/taci antigen-binding molecules |
| US11912781B2 (en) | 2021-01-13 | 2024-02-27 | Visterra, Inc. | Humanized complement 5A receptor 1 antibodies and methods of use thereof |
| US20240150484A1 (en) | 2021-03-12 | 2024-05-09 | Genmab A/S | Non-activating antibody variants |
| US20250313631A1 (en) | 2021-09-16 | 2025-10-09 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| WO2023046979A1 (en) | 2021-09-27 | 2023-03-30 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| AU2022361691A1 (en) * | 2021-10-08 | 2024-03-28 | Genmab A/S | Antibodies binding to cd30 and cd3 |
| WO2023109928A1 (zh) * | 2021-12-16 | 2023-06-22 | 上海宝济药业有限公司 | 抗免疫球蛋白降解酶酶切的Fc变体 |
| CN120092020A (zh) | 2022-07-08 | 2025-06-03 | 新加坡科技研究局 | Cnx抗原结合分子 |
| CA3265385A1 (en) | 2022-08-22 | 2024-02-29 | Abdera Therapeutics Inc. | DLL3 BINDING MOLECULES AND THEIR USES |
| WO2024062073A1 (en) | 2022-09-22 | 2024-03-28 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| GB202218388D0 (en) | 2022-12-07 | 2023-01-18 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| AU2024206166A1 (en) | 2023-01-03 | 2025-06-12 | Hummingbird Bioscience Pte. Ltd. | Her3-binding antibody-drug conjugate |
| CN121002069A (zh) | 2023-01-06 | 2025-11-21 | 泰温治疗私人有限公司 | 抗原结合分子 |
| EP4646439A1 (en) | 2023-01-06 | 2025-11-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
| GB202311050D0 (en) | 2023-07-19 | 2023-08-30 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| WO2025125495A1 (en) | 2023-12-13 | 2025-06-19 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| WO2025133322A1 (en) | 2023-12-22 | 2025-06-26 | Agency For Science, Technology And Research | Cnx antigen-binding molecules |
| GB202405551D0 (en) | 2024-04-19 | 2024-06-05 | Vvb Bio Pte Ltd | Combination treatment |
| GB202408044D0 (en) | 2024-06-06 | 2024-07-24 | Vvb Bio Pte Ltd | gp130 antigen-binding molecules |
| WO2025257350A1 (en) | 2024-06-13 | 2025-12-18 | Singapore Health Services Pte Ltd | Pai-1 antigen-binding molecules |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4568649A (en) | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| JPH02262599A (ja) | 1989-01-03 | 1990-10-25 | Merck & Co Inc | ヒト多形核白血球からの精製Ｃ５ａレセプター |
| AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5284746A (en) | 1990-02-08 | 1994-02-08 | Zymogenetics, Inc. | Methods of producing hybrid G protein-coupled receptors |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| US5844094A (en) | 1992-09-25 | 1998-12-01 | Commonwealth Scientific And Industrial Research Organization | Target binding polypeptide |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| US5480974A (en) | 1993-06-18 | 1996-01-02 | The Scripps Research Institute | Antibodies to human C5a receptor |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US20010036650A1 (en) | 1994-08-16 | 2001-11-01 | Human Genome Sciences, Inc. | C5a receptor |
| US5861272A (en) | 1995-06-02 | 1999-01-19 | Human Genome Sciences, Inc. | C5A receptor |
| JPH08109200A (ja) | 1994-08-19 | 1996-04-30 | Takeda Chem Ind Ltd | 抗Ｃ５ａレセプター抗体、その製造法および用途 |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| WO1996039511A2 (en) | 1995-06-05 | 1996-12-12 | Incyte Pharmaceuticals, Inc. | A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR |
| EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| WO1998033908A1 (en) | 1997-01-31 | 1998-08-06 | Incyte Pharmaceuticals, Inc. | Human c5a-like receptor |
| JP2002505574A (ja) | 1997-04-30 | 2002-02-19 | エンゾン，インコーポレイテッド | ポリアルキレンオキシド修飾された単鎖ポリペプチド |
| US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| WO2002038767A2 (en) | 2000-11-07 | 2002-05-16 | Genetics Institute, Llc. | G protein-coupled receptor protein and nucleic acid molecules and uses therefor |
| AU2002246733B2 (en) | 2000-12-19 | 2007-09-20 | Altor Bioscience Corporation | Transgenic animals comprising a humanized immune system |
| WO2002061087A2 (en) | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| TWI334439B (en) * | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| BRPI0211953B8 (pt) | 2001-08-17 | 2021-05-25 | Genentech Inc | anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro |
| ATE453661T1 (de) | 2001-09-27 | 2010-01-15 | Merck & Co Inc | Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| ES2646792T3 (es) | 2002-01-25 | 2017-12-18 | Novo Nordisk A/S | Anticuerpos monoclonales contra bucles extracelulares de C5aR |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| JP2006513702A (ja) | 2002-09-09 | 2006-04-27 | ヌラ インコーポレーティッド | Ｇタンパク質共役受容体およびその使用 |
| AU2002952086A0 (en) | 2002-10-16 | 2002-11-07 | The University Of Queensland | Treatment of osteoarthritis |
| US7285269B2 (en) * | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
| US7807389B2 (en) | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| WO2004082568A2 (en) | 2003-03-17 | 2004-09-30 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar) |
| US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| JP2007534631A (ja) | 2003-10-28 | 2007-11-29 | ノボ ノルディスク アクティーゼルスカブ | ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用 |
| WO2005060739A1 (en) | 2003-12-24 | 2005-07-07 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| EP1586583A3 (en) | 2004-04-16 | 2005-11-16 | Alligator Bioscience AB (publ) | Compounds that block C5a complement receptor and their use in therapy |
| MX2007011064A (es) * | 2005-03-23 | 2008-02-19 | Genmab As | Anticuerpos contra cd38 para tratamiento de mieloma multiple. |
| WO2007055374A1 (ja) | 2005-11-14 | 2007-05-18 | Mitsubishi Tanabe Pharma Corporation | 骨粗鬆症治療剤 |
| KR20090053899A (ko) * | 2006-08-22 | 2009-05-28 | 지투 인플레메이션 피티와이 엘티디 | 개선된 특성을 갖는 항-ｃ５ａｒ 항체 |
| EP2061812A4 (en) | 2006-08-22 | 2010-06-09 | G2 Inflammation Pty Ltd | METHOD FOR THE PRODUCTION OF ANTIBODIES |
| WO2008030564A2 (en) | 2006-09-08 | 2008-03-13 | Verenium Corporation | Aglycosylated antibodies and methods of making and using those antibodies |
| WO2009053368A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Single ifn-beta fused to a mutated igg fc fragment |
| RU2010138612A (ru) | 2008-02-20 | 2012-03-27 | Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR |
| WO2009149081A1 (en) | 2008-06-02 | 2009-12-10 | Novelmed Therapeutics, Inc. | Method for treating inflammatory conditions |
| US20090324585A1 (en) | 2008-06-12 | 2009-12-31 | The Trustees of the Leland Standford Junior University | Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis |
| WO2010000864A1 (en) | 2008-07-04 | 2010-01-07 | Novo Nordisk A/S | Method for producing monoclonal antibodies |
| RS54998B1 (sr) | 2008-12-22 | 2016-11-30 | Chemocentryx Inc | Antagonisti c5ar |
| WO2011100477A2 (en) | 2010-02-10 | 2011-08-18 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| EP3216462A3 (en) | 2010-02-26 | 2017-12-20 | Novo Nordisk A/S | Stable antibody containing compositions |
| KR20130086144A (ko) | 2010-05-28 | 2013-07-31 | 노보 노르디스크 에이/에스 | 항체 및 보존제를 포함하는 안정한 다중-투여 조성물 |
| EP2588499B1 (en) * | 2010-06-30 | 2020-04-08 | Novo Nordisk A/S | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
| JP2013532176A (ja) * | 2010-07-15 | 2013-08-15 | ノヴォ ノルディスク アー／エス | 安定化させた第ｖｉｉｉ因子バリアント |
| WO2012088247A2 (en) * | 2010-12-22 | 2012-06-28 | Medimmune, Llc | Anti-c5/c5a/c5adesr antibodies and fragments |
| RU2616881C2 (ru) * | 2011-06-06 | 2017-04-18 | Ново Нордиск А/С | Терапевтические антитела |
| WO2014180961A1 (en) | 2013-05-08 | 2014-11-13 | Novo Nordisk A/S | Use of c5ar antagonists |
-
2012
- 2012-06-04 RU RU2013155029A patent/RU2616881C2/ru active
- 2012-06-04 BR BR112013031198-3A patent/BR112013031198B1/pt active IP Right Grant
- 2012-06-04 ES ES20187662T patent/ES2929575T3/es active Active
- 2012-06-04 ES ES12725447.2T patent/ES2693647T3/es active Active
- 2012-06-04 CN CN201280028064.1A patent/CN103596982B/zh active Active
- 2012-06-04 PL PL18175085T patent/PL3424953T3/pl unknown
- 2012-06-04 EP EP20187662.0A patent/EP3798230B1/en active Active
- 2012-06-04 DK DK12725447.2T patent/DK2718322T3/en active
- 2012-06-04 DK DK18175085.2T patent/DK3424953T3/da active
- 2012-06-04 EP EP18175085.2A patent/EP3424953B1/en active Active
- 2012-06-04 DK DK20187662.0T patent/DK3798230T3/da active
- 2012-06-04 PL PL12725447T patent/PL2718322T3/pl unknown
- 2012-06-04 KR KR1020137034239A patent/KR101978757B1/ko active Active
- 2012-06-04 WO PCT/EP2012/060524 patent/WO2012168199A1/en not_active Ceased
- 2012-06-04 EP EP12725447.2A patent/EP2718322B1/en active Active
- 2012-06-04 PT PT181750852T patent/PT3424953T/pt unknown
- 2012-06-04 CA CA2838497A patent/CA2838497C/en active Active
- 2012-06-04 AU AU2012266487A patent/AU2012266487B2/en not_active Ceased
- 2012-06-04 JP JP2014514023A patent/JP6141834B2/ja active Active
- 2012-06-06 TW TW101120198A patent/TWI564305B/zh active
- 2012-06-06 US US13/490,093 patent/US8613926B2/en active Active
-
2013
- 2013-06-18 US US13/920,585 patent/US8846045B2/en active Active
- 2013-11-05 IL IL229254A patent/IL229254A/en active IP Right Grant
-
2014
- 2014-08-25 US US14/467,393 patent/US20150044231A1/en not_active Abandoned
-
2016
- 2016-11-02 US US15/341,550 patent/US10323097B2/en active Active
- 2016-12-07 JP JP2016237458A patent/JP6416177B2/ja active Active
-
2019
- 2019-06-17 US US16/443,736 patent/US10882916B2/en active Active
-
2020
- 2020-12-18 US US17/127,688 patent/US20210238300A1/en not_active Abandoned
-
2023
- 2023-12-11 US US18/536,032 patent/US20240218076A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523408A5 (OSRAM) | ||
| RU2013155029A (ru) | Терапевтические антитела | |
| JP7403505B2 (ja) | Ｃｄ３／ｃｄ３８ ｔ細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法 | |
| US10618957B2 (en) | Antibody molecules which bind CD79 | |
| JP2014509861A5 (OSRAM) | ||
| JP2016505556A5 (OSRAM) | ||
| RU2012151478A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| HRP20201375T1 (hr) | ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE | |
| JP2019506363A5 (OSRAM) | ||
| JP2012525829A5 (OSRAM) | ||
| JP2016507523A5 (OSRAM) | ||
| JP2015533853A5 (OSRAM) | ||
| JP2011514150A5 (OSRAM) | ||
| RU2016125489A (ru) | Нейтрализующие моноклональные человеческие антитела против интерлейкина-33 | |
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| JP2012500020A5 (OSRAM) | ||
| RU2011153932A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Toll-ПОДОБНЫМ РЕЦЕПТОРАМ 2 И ИХ ПРИМЕНЕНИЯ | |
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 | |
| JP2019535306A5 (OSRAM) | ||
| WO2022125712A1 (en) | Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function | |
| JP2013519690A5 (OSRAM) | ||
| AU2021287338B2 (en) | BTLA antibodies | |
| TW202311296A (zh) | 新型多特異性分子 | |
| CN116685601A (zh) | 聚集潜在性降低和疏水性降低的改良抗oxMIF抗体 | |
| US20230374148A1 (en) | Binding molecules that multimerise cd45 |